Full Press Release Details
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
Conference Call and Webcast Today, November 26, 2024 at 4 30 p.m. ET
PASADENA, Calif., November 26, 2024 - Arrowhead Pharmaceuticals, Inc. (NASDAQ ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference call today, November 26, 2024, at 4 30 p.m. ET to discuss the results.
"Arrowhead is well positioned, both individually and with partners, to advance and ultimately commercialize important new medicines using our proprietary TRiMTM technology. We have the potential to impact the lives of millions of patients in need. We believe we now have all the necessary pieces in place to drive significant value for shareholders in the short-term, mid-term, and, more importantly, over the long-term as we seek to build a sustainable, financially sound business," said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. "Key events have occurred during the recent period that we see as potentially transformational for Arrowhead. Earlier this month, we submitted our first NDA to the U.S. FDA for investigational plozasiran, paving the way for Arrowhead to potentially launch our first commercial product in 2025, subject to FDA review and approval. We also took steps to meaningfully strengthen our balance sheet, including entering into a large licensing and collaboration agreement with Sarepta Therapeutics, which was announced today. Sarepta is an important new partner with extensive clinical, regulatory, and commercial expertise and this collaboration will help us advance and commercialize multiple promising Arrowhead-discovered drug candidates that fall outside of our current commercial focus on the cardiometabolic therapeutic area."
Selected Recent Financial Events
Strengthened the balance sheet through a strategic financing agreement and licensing and collaboration agreement. We estimate that together, these transactions extend Arrowhead's cash runway into 2028 and potentially through multiple new drug launches, including wholly owned and partnered programs. These two events were
Signed a licensing and collaboration agreement with Sarepta Therapeutics. Upon closing, Arrowhead will receive $825 million, consisting of $500 million cash and $325 million as an equity investment priced at $27.2507, representing a 35% premium to the 30-day volume weighted average price. Arrowhead also receives $250 million to be paid over five years and is eligible to receive an additional $300 million in near-term payments. Arrowhead is also eligible to receive royalties on commercial sales and approximately $10 billion in potential milestone payments.
Closed a strategic financing agreement with Sixth Street for significant, long-term, non-dilutive capital. The $500 million senior secured credit facility includes $400 million funded at close with an additional $100 million available at Arrowhead's option, subject to mutual agreement between Sixth Street and Arrowhead, during the seven-year term of the agreement.
Selected Recent R D Events
Submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome, a severe and rare genetic disease which currently has no FDA approved treatments.
Received Breakthrough Therapy designation from the FDA for investigational plozasiran as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome.
Announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and SHASTA-2 studies of investigational plozasiran. These data were presented in two oral presentations at the American Heart Association Scientific Sessions 2024 (AHA24) and PALISADE data was simultaneously published in the AHA journal, Circulation. Key results include the following
Plozasiran induced deep and sustained reductions in triglycerides and impacted a wide spectrum of lipoproteins that may be involved with atherosclerotic cardiovascular disease
Similar responses were observed in patients with genetically confirmed and clinically diagnosed familial chylomicronemia syndrome
Mean reductions in triglycerides of up to -73% in patients from MUIR and -86% in patients from SHASTA-2 with favorable reductions in remnant cholesterol and non-HDL-cholesterol were observed through 15 months follow up in the open-label extension
Overall, plozasiran has been generally well-tolerated to date. In the PALISADE study, the most frequently reported treatment emergent adverse events for the 25 mg dose were abdominal pain, COVID-19, nasopharyngitis, and nausea. Across clinical studies and study populations, the most frequently reported treatment emergent adverse events for the 25 mg dose were COVID-19, upper respiratory tract infection, headache, Type 2 diabetes mellitus, and abdominal pain.
Initiated pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in patients with severe hypertriglyceridemia.
Launched a new disease awareness campaign, We'll Get There Soon,' to inspire hope for the rare disease community affected by familial chylomicronemia syndrome.
Presented data from the Phase 3 PALISADE study of plozasiran in a late-breaking oral presentation at the European Society of Cardiology (ESC) Congress 2024 and simultaneously published in The New England Journal of Medicine.
Arrowhead's Verona, WI manufacturing and testing facility successfully completed requirements to manufacture GMP drug substance to support clinical trials conducted in the United States and many other countries abroad, and recently successfully completed a Qualified Person (QP) audit, which allows for internally produced drug substance to be used in support of clinical programs in EU countries and the United Kingdom.
Filed for regulatory clearance in New Zealand to initiate a Phase 1 2a clinical trial of ARO-INHBE, the company's investigational RNAi therapeutic being developed as a potential treatment for obesity.
In preclinical studies ARO-INHBE reduced body weight and fat mass with a novel mechanism of action that may preserve lean muscle mass compared to currently approved obesity therapies.
Completed the 2024 Summer Series of R D webinars, each highlighting a specific therapeutic area in Arrowhead's pipeline, including the following events
May 23, 2024 - Muscular
June 25, 2024 - Cardiometabolic
July 16, 2024 - Pulmonary
August 14, 2024 - Obesity Metabolic
September 25, 2024 - Central Nervous System
Selected Fiscal 2024 Financial Results
ARROWHEAD PHARMACEUTICALS, INC.
CONSOLIDATED CONDENSED FINANCIAL INFORMATION
(in thousands, except per share amounts)
| Year Ended September 30, | |||||||
| OPERATING SUMMARY | 2024 | 2023 | |||||
| Revenue | $ | 3,551 | $ | 240,735 | |||
| Operating Expenses | |||||||
| Research and development | 505,870 | 353,188 | |||||
| General and administrative expenses | 98,761 | 92,549 | |||||
| Total Operating Expenses | 604,631 | 445,737 | |||||
| Operating loss | (601,080) | (205,002) | |||||
| Total other expense | (11,380) | (1,489) | |||||
| Loss before income tax expense and noncontrolling interest | (612,460) | (206,491) | |||||
| Income tax (benefit) expense | (2,767) | 2,784 | |||||
| Net loss including noncontrolling interest | (609,693) | (209,275) | |||||
| Net loss attributable to noncontrolling interest, net of tax | (10,200) | (4,000) | |||||
| Net loss attributable to Arrowhead Pharmaceuticals, Inc. | $ | (599,493) | $ | (205,275) | |||
| Net loss per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted | $ | (5.00) | $ | (1.92) | |||
| Weighted-average shares used in calculating - Diluted | 119,784 | 106,750 |
| September 30, | |||||||
| FINANCIAL POSITION SUMMARY | 2024 | 2023 | |||||
| Cash, cash equivalents and restricted cash | $ | 102,685 | $ | 110,891 | |||
| Investments | 578,276 | 292,735 | |||||
| Total cash resources | 680,961 | 403,626 | |||||
| Other assets | 458,841 | 361,926 | |||||
| Total Assets | $ | 1,139,802 | $ | 765,552 | |||
| Current deferred revenue | $ | - | $ | 866 | |||
| Credit Facility | 393,183 | - | |||||
| Other liabilities | 555,556 | 477,524 | |||||
| Total Liabilities | $ | 948,739 | $ | 478,390 | |||
| Total Arrowhead Pharmaceuticals, Inc. Stockholders' Equity | $ | 185,444 | $ | 271,343 | |||
| Noncontrolling Interest | 5,619 | 15,819 | |||||
| Total Noncontrolling Interest and Stockholders' Equity | $ | 191,063 | $ | 287,162 | |||
| Total Liabilities, Noncontrolling Interest and Stockholders' Equity | $ | 1,139,802 | $ | 765,552 | |||
| Shares Outstanding | 124,376 | 107,312 |
Webcast and Conference Call and Details
Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call.
For analysts that wish to participate in the conference call, please register at https register.vevent.com register BIc060a13ae8224934aac09d48abe7b2f6. Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.
Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of apolipoprotein C-III (APOC3) which is a component of triglyceride rich lipoproteins (TRLs) and a key regulator of triglyceride metabolism. APOC3 increases triglyceride levels in the blood by inhibiting breakdown of TRLs by lipoprotein lipase and uptake of TRL remnants by hepatic receptors in the liver. The goal of treatment with plozasiran is to reduce the level of APOC3, thereby reducing triglycerides and restoring lipids to more normal levels.
In multiple clinical studies, investigational plozasiran has demonstrated reductions in triglycerides and multiple atherogenic lipoproteins in patients with familial chylomicronemia syndrome (FCS), severe hypertriglyceridemia (SHTG), and mixed hyperlipidemia. Plozasiran has been generally well tolerated to date with treatment emergent adverse events reported that generally reflect the comorbidities and underlying conditions of the study populations. Across clinical studies and study populations, the most frequently reported treatment emergent adverse events for the 25 mg dose were COVID-19, upper respiratory tract infection, headache, Type 2 diabetes mellitus, and abdominal pain.
Plozasiran is being investigated in the SUMMIT program of clinical studies, including the PALISADE Phase 3 study in patients with FCS, the SHASTA studies in patients with SHTG, and the MUIR and CAPITAN studies in patients with mixed hyperlipidemia.
Plozasiran in the treatment of patients with FCS has been granted Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation by the U.S. Food and Drug Administration and Orphan Drug Designation by the European Medicines Agency. Investigational plozasiran has not been reviewed or approved to treat any disease.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.
Safe Harbor Statement under the Private Securities Litigation Reform Act
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "hope," "intend," "plan," "project," "could," "estimate," "continue," "target," "forecast" or "continue" or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs our expectations regarding the potential benefits of the partnership, licensing and or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are
based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Arrowhead Pharmaceuticals, Inc.
ir arrowheadpharma.com
LifeSci Advisors, LLC
britchie lifesciadvisors.com
LifeSci Communications, LLC
Kendy Guarinoni, Ph.D.
kguarinoni lifescicomms.com
Source Arrowhead Pharmaceuticals, Inc.